Clover Biopharmaceuticals is based in Shanghai, China. It has raised $1B in total funding. Latest round: IPO. Backed by Hillhouse, Temasek, GL Ventures.
Clover Biopharmaceuticals funding overview
Clover Biopharmaceuticals is based in Shanghai, China. Clover Biopharmaceuticals has raised $1B in total disclosed funding. That places its disclosed total in over $1B. Its most recent disclosed round is an IPO announced in January 2021. The round record for Clover Biopharmaceuticals runs through 2021; nothing later has been disclosed. Investors on record include Hillhouse, Temasek, GL Ventures, CEPI, GSK/Dynavax. 5 distinct backers are named across the disclosed rounds.
Frequently asked about Clover Biopharmaceuticals funding
How much has Clover Biopharmaceuticals raised?
Clover Biopharmaceuticals has raised $1B in total disclosed funding across the rounds on record.
Who has invested in Clover Biopharmaceuticals?
Hillhouse, Temasek, GL Ventures, CEPI, GSK/Dynavax are named among the investors backing Clover Biopharmaceuticals.
What was the latest Clover Biopharmaceuticals funding round?
The most recent disclosed round is an IPO, announced in January 2021.
Where is Clover Biopharmaceuticals based?
Clover Biopharmaceuticals is based in Shanghai, China.
When did Clover Biopharmaceuticals last raise?
The last disclosed Clover Biopharmaceuticals round closed in January 2021 at IPO.
Clover Biopharmaceuticals totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies in Shanghai below to benchmark round size and investor mix.
Companies related to Clover Biopharmaceuticals (32)
